The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Determining when to switch from hydroxyurea to interferon-based therapy in patients with PV
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, discusses considerations for community physicians when choosing between hydroxyurea and interferon therapy in patients with polycythemia vera (PV) and comments on when it may be necessary to switch between these therapies. Although hydroxyurea is attractive in its affordability and simplicity of administration, growing evidence suggests that interferon-based therapy may delay disease progression, potentially making it a better choice for certain patients. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Promedior, Incyte, Genetech, Abbvie, Samus, Celgene, Constellation, CTI BioPharma.- a Sobi Company, Mays Cancer Center, NCI;
Consultancy: Constellation, LaJolla Pharma, Sierra Onc, Novartis.
